Search

Your search keyword '"Jessica Malek"' showing total 7 results
Start Over Author "Jessica Malek"
7 results on '"Jessica Malek"'

2. Data from Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis

Author

Imad Shureiqi, Rena Sue Day, Jessica Malek, Bo Wei, Shailesh Advani, Xiangsheng Zuo, and Peiying Yang

Abstract

Why celecoxib exerts chemopreventive activity in only some familial adenomatous polyposis (FAP) patients remains poorly understood. We conducted a phase II clinical study to identify potential predictive biomarkers for celecoxib chemopreventive activity in FAP. Twenty-seven patients with FAP completed a 6-month oral course of 400 mg of celecoxib twice a day; they underwent colonoscopies before and after celecoxib treatment to assess colorectal polyp tumor burden and to obtain normal and polyp colorectal biopsies to measure celecoxib, 13-S-hydroxyoctadecadienoic acid (13-HODE), 15-HETE, 12-HETE, and LTB4 levels by LC/MS-MS. Celecoxib levels in sera from those patients were also measured before treatment and after 2, 4, and 6 months of treatment. Nineteen of the 27 patients experienced a response to celecoxib, with a ≥ 28% reduction of colonic polyp burden on the basis of a reproducible quantitative assessment of colonoscopy results. Celecoxib levels were significantly lower in polyp tissues than in normal colorectal tissues. Celecoxib levels in sera and normal colorectal tissues were correlated in patients who experienced a response to celecoxib but not in those who did not. Among the measured lipoxygenase products, only 13-HODE levels were significantly lower in polyp tissues than in normal tissues. Our findings demonstrate the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical response in patients with FAP.Prevention Relevance:This study evaluated potential predictive biomarkers for celecoxib chemopreventive activity in patients with FAP. Our findings demonstrated the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical chemopreventive response in patients with FAP.See related Spotlight, p. 205

Published
2023
Full Text
View/download PDF

4. Predicting the occurrence of minor adverse events in cardiac rehabilitation using physical variables

Author

Maria Júlia Lopez Laurino, Dyovana Gomes Pinheiro, Jéssica Malek da Silva, Felipe Ribeiro, Heloisa Balotari Valente, and Luiz Carlos Marques Vanderlei

Subjects
Cardiac rehabilitation, Exercise, Cardiovascular diseases, Acute events, Risk factors, Medicine, Science
Abstract

Abstract The safety of exercise practice by individuals with cardiovascular disease is due to a good clinical evaluation to identify patients with a higher risk of adverse events, thus the study of simple variables capable of predicting the rate of events during exercise is relevant and may provide better screening tools to be applied in the clinical practice. The study aimed to evaluate if clinical and physical parameters can predict the rate of adverse events during exercise-based cardiac rehabilitation. This was a cohort study that followed 73 patients during 24 sessions of exercise. Were registered 217 simple adverse events, at a rate of 2.5 events per hour of exercise. We found that higher adiposity, worse pulmonary function, lower functional capacity, and reduced heart rate variability were significant and acceptable predictors of adverse events during exercise, according to the ROC curve analysis. We state that these simple physical parameters may be useful for cardiac risk stratification in cardiac rehabilitation programs with low resources, contributing to its safety.

Published
2024
Full Text
View/download PDF

5. Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients

Author

Imad Shureiqi, Peiying Yang, Jessica Malek, Shailesh Advani, Rena S. Day, Bo Wei, and Xiangsheng Zuo

Subjects
musculoskeletal diseases, Cancer Research, medicine.medical_specialty, Colon, Colorectal cancer, Biological Availability, Colonoscopy, Gastroenterology, Article, Familial adenomatous polyposis, Internal medicine, Quantitative assessment, medicine, Humans, In patient, Cyclooxygenase Inhibitors, heterocyclic compounds, neoplasms, Sulfonamides, medicine.diagnostic_test, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Colonic Polyp, medicine.disease, Response Variability, digestive system diseases, Bioavailability, Adenomatous Polyposis Coli, Oncology, Celecoxib, Colorectal Polyp, Pyrazoles, lipids (amino acids, peptides, and proteins), business, medicine.drug
Abstract

Why celecoxib exerts chemopreventive activity in only some familial adenomatous polyposis (FAP) patients remains poorly understood. We conducted a phase II clinical study to identify potential predictive biomarkers for celecoxib chemopreventive activity in FAP. Twenty-seven patients with FAP completed a 6-month oral course of 400 mg of celecoxib twice a day; they underwent colonoscopies before and after celecoxib treatment to assess colorectal polyp tumor burden and to obtain normal and polyp colorectal biopsies to measure celecoxib, 13-S-hydroxyoctadecadienoic acid (13-HODE), 15-HETE, 12-HETE, and LTB4 levels by LC/MS-MS. Celecoxib levels in sera from those patients were also measured before treatment and after 2, 4, and 6 months of treatment. Nineteen of the 27 patients experienced a response to celecoxib, with a ≥ 28% reduction of colonic polyp burden on the basis of a reproducible quantitative assessment of colonoscopy results. Celecoxib levels were significantly lower in polyp tissues than in normal colorectal tissues. Celecoxib levels in sera and normal colorectal tissues were correlated in patients who experienced a response to celecoxib but not in those who did not. Among the measured lipoxygenase products, only 13-HODE levels were significantly lower in polyp tissues than in normal tissues. Our findings demonstrate the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical response in patients with FAP.Prevention Relevance:This study evaluated potential predictive biomarkers for celecoxib chemopreventive activity in patients with FAP. Our findings demonstrated the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical chemopreventive response in patients with FAP.See related Spotlight, p. 205

Published
2020
Full Text
View/download PDF

6. Analysis of Barriers to Public and Private Cardiac Rehabilitation Programs in Patients with Low and High Adherence

Author

Lorena Altafin Santos, Dyovana Gomes Pinheiro, Jéssica Malek da Silva, Giovanna Lombardi Bonini Borges, Paula Fernanda da Silva, Ana Laura Ricci-Vitor, and Luiz Carlos Marques Vanderlei

Subjects
Cardiac Rehabilitation, Health Services Accessibility, Attitude of Health Personnel, Choice Behavior, Patient Preference, Cardiovascular Diseases., Surgery, RD1-811, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

ABSTRACT Introduction: Participants in cardiac rehabilitation programs have low adherence to their sessions, which makes extremely important to recognize the barriers that cause non-adherence, identifying whether the type of service and level of adherence influence these barriers. Methods: This is a cross-sectional observational study, in which 220 individuals (66.80±11.59 years) of both genders who are members of public and private exercise-based cardiac rehabilitation programs participated. The volunteers were divided according to the level of adherence, considering patients with low adherence (PLA) those with < 70% of attendance and high adherence (PHA) those with > 70%. Then, initial evaluation, Cardiac Rehabilitation Barriers Scale, analysis of socioeconomic level, Hospital Anxiety and Depression Scale, and Mini-Mental State Examination were applied. Results: Higher total barriers were found in PLA in the public service compared to PHA in the private service (P=0.023). In the subscale “perceived need”, PHA in the public service showed higher values than PLA and PHA in the private service (P≤0.001). The “access” barrier was higher for PHA in the public service when compared to PHA in the private service (P=0.024). PHA in the public service exhibited a higher barrier regarding questions about distance, transportation problems, cost, and time constraints. Conclusion: The public program presents higher barriers in the questions and categories compared to the private program, mainly the PHA. Furthermore, there are differences in the profile of the participants regarding socioeconomic and anxiety levels, treatment time, ethnicity, and city where they live.

Published
2023
Full Text
View/download PDF

7. Examining Barriers to Adherence and Motives for Engagement and Motivation Among Cardiovascular Rehabilitation Participants.

Author

da Silva JM, de Melo Ghisi GL, da Silva PF, da Cruz MMA, Santos LA, and Vanderlei LCM

Subjects
Humans, Male, Female, Cardiovascular Diseases psychology, Middle Aged, Aged, Motivation, Cardiac Rehabilitation methods, Cardiac Rehabilitation psychology, Patient Compliance psychology
Abstract

Competing Interests: All authors declare no conflicts of interest.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results